Dextromethorphan improved cyclosporine-induced depression in mice model of despair

Azadeh Mesripour , Mojgan Golbidi, Valiollah Hajhashemi

Abstract


Background and purpose: Cyclosporine (Cyc) is a calcineurin inhibitor used in immunosuppressive therapy that may cause psychological problems such as depression. Previous investigations have shown the positive antidepressant effects of dextromethorphan (Dxt). Therefore, the aim of this study was the evaluation of the Dxt effect on Cyc-induced depression in an animal model of despair in two separate cohorts.

Experimental approach: Male albino mice were used, first total activity was evaluated by the locomotor test, and then after that, the immobility time during the forced swimming test was measured as an indicator of depression. Cyc, Dxt, and fluoxetine (the reference antidepressant drug) were all administered IP. Tests were performed either 4 h after injection (cohort 4 h) or in separate groups 24 h after injection (cohort 24 h).

Findings/Results: Cyc reduced total activity measured after 4 h in the locomotor test and it was normalized after 24 h. Immobility time dose-dependently increased during the forced swimming test and remained so after 24 h (cohort 24 h; Cyc 10, 20, and 40 mg/kg, 157 ± 22, 180 ± 8, and 228 ± 4 s, respectively; Cyc 40 mg/kg P < 0.001 vs control 142 ± 13 s) that indicated Cyc induced depressive-like behavior. Dxt (30 mg/kg) like fluoxetine reduced the immobility time when co-administered with Cyc compared with Cyc and remained effective after 24 h (cohort 24 h; 120 ± 30, P < 0.001 vs Cyc 40 mg/kg alone).

Conclusion and implications: Dxt was a useful drug for preventing Cyc-induced depression that remained effective for 24 h in mice. Since interpretation from animal studies to humans must be done with caution further clinical studies on the effect of Dxt in patients suffering from psychological side effects of Cyc may be reasonable.

 


Keywords


Calcineurin; Cyclosporine; Depression; Dextromethorphan.

Full Text:

PDF

References


Wijdicks EF. Neurotoxicity of immunosuppressive drugs. Liver Transpl. 2001;7:937-942.

DOI: 10.1053/jlts.2001.27475.

Mansuy IM. Calcineurin in memory and bidirectional plasticity. Biochem Biophys Res Commun. 2003;311(4):1195-1208.

DOI: 10.1016/j.bbrc.2003.10.046.

Sato Y, Takayanagi Y, Onaka T, Kobayashi E. Impact of cyclosporine upon emotional and social behavior in mice. Transplantation. 2007;83(10):1365-1370.

DOI: 10.1097/01.tp.0000263332.65519.1f.

Yu JJ, Zhang Y, Wang Y, Wen ZY, Liu XH, Qin J, et al. Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway. Psychopharmacology (Berl). 2013;225(2):361-372.

DOI: 10.1007/s00213-012-2823-9.

Gong R, Park CS, Abbassi NR, Tang SJ. Roles of glutamate receptors and the mammalian target of rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in hippocampal neurons. J Biol Chem. 2006;281(27):18802-18815.

DOI: 10.1074/jbc.M512524200.

Abelaira HM, Réus GZ, Neotti MV, Quevedo J. The role of mTOR in depression and antidepressant responses. Life Sci. 2014;101(1-2):10-14.

DOI: 10.1016/j.lfs.2014.02.014.

Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR. Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016;159:1-22.

DOI: 10.1016/j.pharmthera.2016.01.016.

Lauterbach EC. Dextromethorphan as a potential rapid-acting antidepressant. Med Hypotheses. 2011;76(5):717-719.

DOI: 10.1016/j.mehy.2011.02.003.

Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959-964.

DOI: 10.1126/science.1190287.

Mesripour A, Purhasani A, Hajhashemi V. N-methyl-D-aspartate receptor antagonists decrease interferon-alpha induced depressive behavior in mice model of despair. Thai J Pharm Sci. 2019;43(1):8-13.

Pacheco-López G, Doenlen R, Krügel U, Arnold M, Wirth T, Riether C, et al. Neurobehavioural activation during peripheral immunosuppression. Int J Neuropsychopharmacol. 2013;16(1):137-149.

DOI: 10.1017/S1461145711001799.

Piras G, Giorgi O, Corda MG. Effects of antidepressants on the performance in the forced swim test of two psychogenetically selected lines of rats that differ in coping strategies to aversive conditions. Psychopharmacology (Berl). 2010;211(4):403-414.

DOI: 10.1007/s00213-010-1904-x.

Mesripour A, Hajhashemi V, Kuchak A. Effect of concomitant administration of three different antidepressants with vitamin B6 on depression and obsessive compulsive disorder in mice models. Res Pharm Sci. 2017;12(1):46-52.

DOI: 10.4103/1735-5362.199046.

Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol. 1997;8(6-7):523-532.

DOI: 10.1097/00008877-199711000-00010.

Deussing JM. Animal models of depression. Drug Discov Today Dis Models. 2006;3(4):375-383.

DOI: 10.1016/j.ddmod.2006.11.003.

Miyakawa T, Leiter LM, Gerber DJ, Gainetdinov RR, Sotnikova TD, Zeng H, et al. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A. 2003;100(15):8987-8992.

DOI: 10.1073/pnas.1432926100.

Lauterbach EC. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Med Hypotheses. 2012;78(6):693-702.

DOI: 10.1016/j.mehy.2012.02.012.

Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010;33(2):67-75.

DOI: 10.1016/j.tins.2009.11.003.

Yoon SC, Seo MS, Kim SH, Jeon WJ, Ahn YM, Kang UG, et al. The effect of MK-801 on mTOR/p70S6K and translation-related proteins in rat frontal cortex. Neurosci Lett. 2008;434(1):23-28.

DOI: 10.1016/j.neulet.2008.01.020.

Liu Y, Qin L, Li G, Zhang W, An L, Liu B, et al. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther. 2003;305(1):212-218.

DOI: 10.1124/jpet.102.043166.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.